Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2022219 | 0.89 | GRM2 (0.46) | GRM2GRIN2BALDH1A1HCRTR2HCRTR1 | |
| SCHEMBL1003022 | 0.88 | CHRM5 (0.47) | GRM2GRIN2BALDH1A1HCRTR2HCRTR1 | |
| SCHEMBL2022287 | 0.88 | GRM2 (0.45) | GRM2GRIN2BALDH1A1HCRTR2HCRTR1 | |
| SCHEMBL1003383 | 0.87 | GRM2 (0.47) | GRM2GRIN2BALDH1A1HCRTR2HCRTR1 | |
| SCHEMBL12581822 | 0.87 | GRM2 (0.51) | GRM2GRIN2BALDH1A1HCRTR2HCRTR1 | |
| SCHEMBL2022956 | 0.86 | GRM2 (0.44) | GRM2GRIN2BALDH1A1HCRTR2HCRTR1 | |
| SCHEMBL12413546 | 0.86 | HCRTR1 (0.52) | GRM2GRIN2BHCRTR2HCRTR1 | |
| SCHEMBL1000919 | 0.84 | GRM2 (0.45) | GRM2GRIN2BALDH1A1HCRTR2HCRTR1 | |
| SCHEMBL12581714 | 0.84 | GRM2 (0.45) | GRM2GRIN2BALDH1A1HCRTR2HCRTR1 | |
| SCHEMBL2021006 | 0.83 | ALDH1A1 (0.49) | GRM2GRIN2BALDH1A1HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | VAN WAGENEN BRADFORD | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | GRM2 3/4885GRIN2B 11/4885ALDH1A1 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.